CTOs on the Move

Abeona Therapeutics

www.abeonatherapeutics.com

 
Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company`s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company`s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Brian Kevany
 Chief Technical Officer Profile

Funding

Abeona Therapeutics raised $15.5M on 08/03/2015
Abeona Therapeutics raised $13.8M on 10/16/2017
Abeona Therapeutics raised $92M on 10/19/2017
Abeona Therapeutics raised $103.5M on 12/28/2019

Similar Companies

Nemus Bioscience

Nemus Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, designed to alleviate a variety of diseases and symptoms by selectively targeting CB1 and CB2 receptors. NEMUS Bioscience Inc. is developing a novel and proprietary class of product candidates that are designed to target the body`s nervous and immune systems without inducing many of the undesirable side effects typically associated with currently available therapeutics. NEMUS Bioscience Inc., a Nevada corporation is listed on the OTC Bulletin Board and trading under the symbol NMUS. To become a leading developer of cannabis-based therapeutics to address unmet medical needs on a global basis.

CellCarta

CellCarta provides integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as digital pathology & AI.

SimBioSys Inc

SimBioSys Inc is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cogent Biosciences

Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent`s lead therapeutic candidate, PLX9486 (expected to be named CGT9486 in the future), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the body. We are also studying PLX9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling.

Oncology Plus

Oncology Plus is a Brandon, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.